Cipla reports weaker profits in the September quarter, with multiple outlets citing pressure from its US business and related cost impacts. Business Line notes net profit of ₹878 crore for the quarter ended September 30, down sharply year on year, while another Business Line piece highlights muted US sales as a key factor.
Several sources also describe partial offsetting strength in India and ongoing expectations for the US to recover. Economic Times points to approvals for respiratory products and a growing biosimilar pipeline as drivers of medium-term optimism, alongside product launches despite declining operating margins. NDTV focuses more on regional cost and revenue pressure, referencing a Middle East freight squeeze affecting Q2 costs and a North America revenue goal of $1 billion, which Business Line also reiterates.
One outlet adds analyst expectations: NDTV’s preview frames the quarter with estimates for profit decline and minimal revenue growth, giving a forward-looking view on US headwinds. Across coverage, the shared theme is near-term profitability pressure alongside stated plans for margin and revenue improvement.
